Hemoglobinopathy Market, by Test Type (Routine Red Blood Cell (RBC) count, Genetic Testing, Hemoglobin by high performance liquid chromatography, Hemoglobin isoelectric focusing (Hb IEF), Hemoglobin electrophoresis (Hb ELP), Hemoglobin solubility test), by Indication (Sickle Cell Disease, Beta Thalassemia, Alpha Thalassemia), by End User (Hospitals, Diagnostic Laboratories, Clinics), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
The global hemoglobinopathy market is estimated to be valued at US$ 636.9 million in 2023 and is expected to exhibit a CAGR of 5.9% during the forecast period (2023-2030).
Global Hemoglobinopathy Market – Driver
Increasing awareness programs for sickle cell disease
Hemoglobinopathy Market Report Coverage
Market- Trends Section:
Increasing awareness programs for sickle cell disease
Increasing awareness programs by government bodies is expected to drive the hemoglobinopathy market over the forecast period. For instance, in November 2020, The European Hematology Association (EHA) Topics-in-Focus Hemoglobinopathies Program (focus on Sickle Cell Disease) was launched to expand awareness and education about these increasingly common genetic diseases in Europe, among healthcare professionals, patients and the general population.
The global hemoglobinopathy market report is segmented into Test Type, Indication, End User and Region
U.S.: 
U.K. : 
India : 
